ClinicalTrials.gg
RecruitingNCT07220616Updated Aug 24, 2026

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

A Phase 1/2 interventional study of DS3790a and Combination drug in Hematological Malignancies and B-cell Non-Hodgkin Lymphoma, sponsored by Daiichi Sankyo. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Planned enrollment
15th of 107
420 · median 106
Started
2026
with 10 others
Phase 1/2
17 of 142
6 open now
Primary completion
2030-11
later than 51 of 57 live
Registered
134th of 142
by date

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 15th largest by planned enrollment of the 107 interventional ones that give a count, is one of 11 that started in 2026, is one of 17 in phase 1/2, reaches primary completion later than 51 of the 57 other live ones, and was the 134th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 424 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 315 Hematologic Neoplasms studies recruiting now, 211 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Read the detailed description

DS3790a may be effective in the treatment of patients with hematological malignancies. The primary objective of this study will assess the safety and preliminary efficacy of DS3790a monotherapy and combination regimens.

03

Conditions studied

  • Hematological Malignancies
  • B-cell Non-Hodgkin Lymphoma

Keywords

  • Hematological Malignancies
  • DS3790a
  • B-cell non-Hodgkin lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. Sign and date the ICF, prior to the start of any trial-specific procedures.
  2. Adults >=18 years at the time the ICF is signed.
  3. History of one of the documented hematologic according to the 5th edition of WHO classification as specified in the protocol.
  4. NHL participants only: Agree to provide baseline tumor tissue samples as specified in the protocol.
  5. PS of 0, 1 or 2 assessed no more than 14 days prior to initiation of trial intervention.
  6. Has adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol.
  7. Has an >=50% by either an ECHO or MUGA within 28 days before the trial starts.
  8. of at least 3 months.
  9. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other trial procedures, and trial restrictions.
  10. A woman of is eligible to participate if she meets all criteria as specified in the protocol.
  11. A male participant capable of producing sperm is eligible to participate if he agrees to all criteria as specified in the protocol.

An individual who meets any of the following criteria will be excluded from participating in this trial:

  1. Prior Allo-SCT.
  2. Prior solid organ transplantation.
  3. Inadequate before initiation of trial intervention as specified in the protocol.
  4. Evidence of brain or (spinal cord or ) based on history and physical examination, unless treated and with radiologically documented lack of progression within 4 weeks prior to initiation of trial intervention.
  5. Uncontrolled or significant cardiovascular disease as specified in the protocol.
  6. Any of the following within the past 6 months prior to enrollment: cerebrovascular accident, , or other arterial thromboembolic event.
  7. Has a history of (noninfectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  8. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder and any , connective tissue, or inflammatory disorder with potential pulmonary involvement, or prior pneumonectomy.
  9. Has been diagnosed with another malignancy within the previous 3 years.
  10. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and lymphocytopenia) not yet resolved to Version 5.0, Grade \<=1 or baseline.
  11. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  12. Has active or uncontrolled , , or infections.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation Phase

    Participants with hematological malignancies who received DS3790a monotherapy.

    Drug: DS3790a

  • Experimental
    Monotherapy Dose Expansion Phase

    Participants with hematological malignancies who received DS3790a monotherapy.

    Drug: DS3790a

  • Experimental
    Cohort A Combination Dose-escalation Phase

    Participants with hematological malignancies who received DS3790a monotherapy and selected combination regimen.

    Drug: DS3790a · Drug: Combination drug

  • Experimental
    Cohort A Randomization/Optimization Phase

    Participants with hematological malignancies who received DS3790a monotherapy and selected combination regimen.

    Drug: DS3790a · Drug: Combination drug

  • Experimental
    Cohort A Phase 2

    Participants with hematological malignancies who received DS3790a monotherapy and selected combination regimen.

    Drug: DS3790a · Drug: Combination drug

  • Experimental
    Cohort B Combination Dose-escalation Phase

    Participants with hematological malignancies who received DS3790a monotherapy and selected combination regimen.

    Drug: DS3790a · Drug: Combination drug

  • Experimental
    Cohort B Randomization/Optimization Phase

    Participants with hematological malignancies who received DS3790a monotherapy and selected combination regimen.

    Drug: DS3790a · Drug: Combination drug

  • Active comparator
    Standard of Care

    Participants with hematological malignancies who received standard of care (SoC).

    Drug: Combination drug

Interventions

  • DrugDS3790a

    Administered as specified in the protocol

  • DrugCombination drug

    Administered as specified in the protocol

  • DrugCombination drug

    Administered as specified in the protocol

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological Malignancies

    Adverse events (AEs) will be graded using NCI-CTCAE version 5.0.

    Time frame: Baseline up to 5 years

  2. Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2)

    Complete Response (CR) is defined as participants with CR as measured by BICR assessment.

    Time frame: Baseline up to 5 years

  3. Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase)

    Complete Response (CR) is defined as participants with CR as measured by investigator assessment.

    Time frame: Baseline up to 5 years

Secondary outcomes

  1. Objective Response by Investigator Assessment In Participants With Hematological Malignancies

    Objective response (OR) is defined as participants with complete response (CR) or partial response (PR) as measured by investigator assessment.

    Time frame: Baseline up to 5 years

  2. Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Complete response (CR) is defined as participants with CR as best overall response (BOR) as measured by investigator assessment.

    Time frame: Baseline up to 5 years

  3. Disease Control in Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Disease control (DC) is defined as participants with CR, PR or stable disease as BOR as measured by investigator assessment.

    Time frame: Baseline up to 5 years

  4. Duration of Complete Response and Duration of Response in Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Duration of Complete Response (DoCR) is defined as the time from the date of first documentation of CR to the first documentation of objective tumor progression by investigator assessment or to death due to any cause, whichever occurs first. DoCR will be calculated for responders (CR) only. Duration of Response (DoR) is defined as the time from the date of first documentation of objective response (CR or PR) to the first documentation of objective tumor progression by investigator assessment or to death due to any cause, whichever occurs first. DoR will be calculated for responders (CR or PR) only.

    Time frame: Baseline up to 5 years

  5. Time to Response in Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Time to Response (TTR) is defined as the time from the date of the start of trial intervention or randomization if randomized, to the date of the first documentation of objective response (CR or PR) by investigator assessment. TTR will be calculated for responders (CR or PR) only.

    Time frame: Baseline up to 5 years

  6. Progression-free Survival Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Progression-free Survival (PFS) is defined as time from the date of the start of trial intervention or randomization if randomized, to the date of radiographic disease progression, defined as the first documented objective PD by investigator assessment or death due to any cause.

    Time frame: Baseline up to 5 years

  7. Overall Survival Participants With Hematological Malignancies by Investigator Assessment (Monotherapy Dose Escalation, Dose Expansion, and Cohorts A and B Dose Escalation)

    Overall Survival (OS) is defined as the time from the date of the start of trial intervention or randomization if randomized, to the date of death due to any cause.

    Time frame: Baseline up to 5 years

07

Study locations

8 of 8 sites recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Lille, 59037, France
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Pierre-Bénite, 69495, France
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Villejuif, 94800, France
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Bologna, 40138, Italy
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Nagoya, 464-8681, Japan
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Tokyo, 104-0045, Japan
    Recruiting
    • Principal Investigator · Contact
  • Research Site
    Tokyo, 135-8550, Japan
    Recruiting
    • Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that have reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2030, 58 months after the start.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 58 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Oct 24, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07220616
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Jan 16, 2026
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Aug 24, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion